In the primary outcome of the VERONA trial, adding venetoclax to azacitidine for the treatment of higher-risk MDS shows no mortality benefit; improvements in secondary outcomes are more favorable.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/high-risk-myelodysplastic-syndromes-combo-falls-short-2025a1000nxl?src=rss
Author :
Publish date : 2025-09-10 13:52:00
Copyright for syndicated content belongs to the linked Source.